Otsuka (OTCMKTS:OTSKY) Stock Price Passes Below 50 Day Moving Average – Here’s What Happened

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $34.98 and traded as low as $32.50. Otsuka shares last traded at $32.52, with a volume of 50,295 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on OTSKY shares. Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a report on Friday, February 27th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Otsuka Price Performance

The stock has a fifty day moving average of $34.98 and a two-hundred day moving average of $32.09. The stock has a market capitalization of $34.93 billion and a price-to-earnings ratio of 13.72. The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05.

Otsuka (OTCMKTS:OTSKY) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. The firm had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, equities research analysts forecast that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.99 earnings per share for the current year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.